JP4588791B2 - 微粒子油性懸濁液を含む医薬組成物 - Google Patents

微粒子油性懸濁液を含む医薬組成物 Download PDF

Info

Publication number
JP4588791B2
JP4588791B2 JP2008558013A JP2008558013A JP4588791B2 JP 4588791 B2 JP4588791 B2 JP 4588791B2 JP 2008558013 A JP2008558013 A JP 2008558013A JP 2008558013 A JP2008558013 A JP 2008558013A JP 4588791 B2 JP4588791 B2 JP 4588791B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
suspension
pharmaceutical
average particle
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008558013A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2008099615A1 (ja
Inventor
泰紀 佐藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aska Pharmaceutical Co Ltd
Original Assignee
Aska Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aska Pharmaceutical Co Ltd filed Critical Aska Pharmaceutical Co Ltd
Publication of JPWO2008099615A1 publication Critical patent/JPWO2008099615A1/ja
Application granted granted Critical
Publication of JP4588791B2 publication Critical patent/JP4588791B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2008558013A 2007-02-16 2008-02-15 微粒子油性懸濁液を含む医薬組成物 Expired - Fee Related JP4588791B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007035916 2007-02-16
JP2007035916 2007-02-16
PCT/JP2008/000230 WO2008099615A1 (ja) 2007-02-16 2008-02-15 微粒子油性懸濁液を含む医薬組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010040362A Division JP2010120974A (ja) 2007-02-16 2010-02-25 微粒子油性懸濁液を含む医薬組成物

Publications (2)

Publication Number Publication Date
JPWO2008099615A1 JPWO2008099615A1 (ja) 2010-05-27
JP4588791B2 true JP4588791B2 (ja) 2010-12-01

Family

ID=39689861

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008558013A Expired - Fee Related JP4588791B2 (ja) 2007-02-16 2008-02-15 微粒子油性懸濁液を含む医薬組成物
JP2010040362A Pending JP2010120974A (ja) 2007-02-16 2010-02-25 微粒子油性懸濁液を含む医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010040362A Pending JP2010120974A (ja) 2007-02-16 2010-02-25 微粒子油性懸濁液を含む医薬組成物

Country Status (9)

Country Link
US (1) US8309138B2 (cg-RX-API-DMAC7.html)
EP (1) EP2123255B1 (cg-RX-API-DMAC7.html)
JP (2) JP4588791B2 (cg-RX-API-DMAC7.html)
KR (1) KR101434706B1 (cg-RX-API-DMAC7.html)
CN (1) CN101610754A (cg-RX-API-DMAC7.html)
AU (1) AU2008215659B2 (cg-RX-API-DMAC7.html)
CA (1) CA2677842C (cg-RX-API-DMAC7.html)
ES (1) ES2423929T3 (cg-RX-API-DMAC7.html)
WO (1) WO2008099615A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ591810A (en) 2008-09-17 2012-12-21 Chiasma Inc Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
CN103655512B (zh) * 2013-12-12 2015-05-20 海南海力制药有限公司 一种硝酸芬替康唑阴道软胶囊及其制备方法
EP4527456A3 (en) 2015-02-03 2025-05-21 Amryt Endo, Inc. Treating acromegaly with oral octreotide
US11576914B2 (en) 2017-07-26 2023-02-14 The Doshisha Drug for treating or preventing disorder caused by TGF-β signaling, and application thereof
EP3668957A4 (en) * 2017-08-17 2021-06-02 University of Delaware Furan based compositions and methods of making thereof
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8546591A (en) 1990-09-13 1992-04-15 Smithkline Beecham Corporation Non-aqueous liquid oral suspensions
MX9300141A (es) 1992-01-13 1994-07-29 Smithkline Beecham Corp Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
JPH0616556A (ja) 1992-07-02 1994-01-25 Yoshitomi Pharmaceut Ind Ltd 難溶性薬物含有製剤
US5656290A (en) * 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5651983A (en) 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
JPH07138151A (ja) 1993-11-15 1995-05-30 Kanebo Ltd ソフトカプセル剤及びその製造方法
DE10399017I1 (de) 1995-02-13 2012-05-16 Searle & Co Substituierte isoxazole zur Behandlung von entzuendung
JPH1081621A (ja) 1996-04-01 1998-03-31 Takeda Chem Ind Ltd 経口投与用医薬組成物
JP2000516244A (ja) 1996-08-22 2000-12-05 リサーチ・トライアングル・ファーマシューティカルズ 水不溶性物質の微粒子を含む組成物およびその製造方法
US5736151A (en) * 1996-12-09 1998-04-07 Pharmacia & Upjohn Company Antibiotic oil suspensions
TR200000235T2 (tr) 1997-05-22 2000-05-22 G.D. Searle &Co. p38 kinaz inhibitörleri olarak ikame edilmiş pirazoller.
CA2320087C (en) 1998-02-09 2006-12-19 Joel Bolonick Treatment of chronic inflammatory disorders of the gastrointestinal tract
JPH11302156A (ja) 1998-04-16 1999-11-02 Tanabe Seiyaku Co Ltd ポリペプチドの微粒子化方法
JP4191825B2 (ja) 1998-09-10 2008-12-03 あすか製薬株式会社 ５−アミノイソキサゾール誘導体
PE20001227A1 (es) * 1998-10-30 2000-11-06 Hoffmann La Roche Procesos para producir una composicion de isotretinoina
AU769610B2 (en) * 1998-12-23 2004-01-29 Amgen, Inc. Polyol/oil suspensions for the sustained release of proteins
WO2000039116A1 (en) 1998-12-25 2000-07-06 Teikoku Hormone Mfg. Co., Ltd. Aminopyrazole derivatives
WO2000040220A1 (en) 1999-01-06 2000-07-13 Korea Research Institute Of Chemical Technology Method of preparing pharmaceutical active ingredient comprising water-insoluble drug and pharmaceutical composition for oral administration comprising the same
SK286371B6 (sk) * 1999-02-23 2008-08-05 Merck & Co., Inc. Farmaceutický prostriedok
KR100449215B1 (ko) 1999-04-23 2004-09-18 다케다 야쿠힌 고교 가부시키가이샤 5-피리딜-1,3-아졸 화합물, 이의 제조 방법 및 이의 용도
DE60016617T2 (de) * 1999-10-01 2005-04-28 Natco Pharma Ltd., Banjara Hills Magensaftresistente gelartige weichkapsel
IN192188B (cg-RX-API-DMAC7.html) * 2000-06-16 2004-03-13 Ranbaxy Lab Ltd
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
DE60104206T2 (de) 2000-09-22 2005-09-22 Galephar M/F Halbfeste arzneizubereitung enthaltend isotretinoin
KR20040073493A (ko) 2001-12-20 2004-08-19 파마시아 코포레이션 경구 투여용 제약 현탁액
JP4611641B2 (ja) 2002-03-20 2011-01-12 エラン ファーマ インターナショナル，リミティド Ｍａｐキナーゼ阻害剤のナノ粒子組成物
GB0214268D0 (en) 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
ATE374201T1 (de) 2002-08-06 2007-10-15 Hoffmann La Roche 6-alkoxypyridopyrimidine als inhibitoren der p-38-map-kinase
DE10237883A1 (de) 2002-08-19 2004-03-04 Merckle Gmbh Chem.-Pharm. Fabrik Substituierte Isoxazolderivate und ihre Verwendung in der Pharmazie
AU2003255843A1 (en) 2002-08-23 2004-03-11 Ionix Pharmaceuticals Limited 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
JP2004099442A (ja) 2002-09-04 2004-04-02 Nisshin Pharma Inc 難溶性薬物含有製剤およびその製造方法
WO2004022555A1 (en) 2002-09-06 2004-03-18 Vertex Pharmaceuticals Incorporated Isoxazoles and their use in the treatment of ischemic diseases
EA011708B1 (ru) 2002-12-18 2009-04-28 Алгоркс Фармасьютикалз, Инк. Применение транс- капсаицина
ES2264795T3 (es) 2003-02-14 2007-01-16 Pfizer Products Inc. Triazolo-piridinas como compuestos antiinflamatorios.
CA2515939A1 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Novel compounds
WO2004073692A1 (ja) 2003-02-18 2004-09-02 Yamashita, Shinji 難水溶性薬物のハードカプセル剤
JP2005013938A (ja) 2003-06-27 2005-01-20 Canon Inc 脱色装置及び方法
US20060151899A1 (en) 2003-08-06 2006-07-13 Akira Kato Process for producing drug ultramicroparticle and apparatus therefor
JP5096658B2 (ja) 2003-10-06 2012-12-12 株式会社三協 生物学的利用能を向上させたソフトカプセル
GB0402143D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
AU2005219525B2 (en) 2004-02-27 2011-08-18 F. Hoffmann-La Roche Ag Fused derivatives of pyrazole
SI2275098T1 (sl) * 2004-05-04 2012-12-31 Hormos Medical Ltd. Nove oralne formulacije ospemifena
US8758821B2 (en) 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
CN101080404B (zh) * 2004-12-28 2011-06-08 Aska制药株式会社 嘧啶基异噁唑衍生物
JP2007039408A (ja) 2005-08-05 2007-02-15 Unitec Foods Co Ltd 微粉化クレアチンとその製造方法

Also Published As

Publication number Publication date
EP2123255A4 (en) 2010-06-02
EP2123255A1 (en) 2009-11-25
CA2677842A1 (en) 2008-08-21
JPWO2008099615A1 (ja) 2010-05-27
AU2008215659A1 (en) 2008-08-21
CN101610754A (zh) 2009-12-23
ES2423929T3 (es) 2013-09-25
US20100092565A1 (en) 2010-04-15
KR101434706B1 (ko) 2014-08-26
WO2008099615A1 (ja) 2008-08-21
KR20090117894A (ko) 2009-11-13
EP2123255B1 (en) 2013-05-15
US8309138B2 (en) 2012-11-13
AU2008215659B2 (en) 2012-11-01
JP2010120974A (ja) 2010-06-03
CA2677842C (en) 2014-09-16

Similar Documents

Publication Publication Date Title
JP4588791B2 (ja) 微粒子油性懸濁液を含む医薬組成物
ES2496144T3 (es) Formulación de cápsulas de pirfenidona y excipientes farmacéuticamente aceptables
KR101454086B1 (ko) 이마티닙 메실레이트의 안정화된 무정형 형태
Zhou et al. Preparation of tripterine nanostructured lipid carriers and their absorption in rat intestine
TW200821298A (en) Pharmaceutical compositions
JPWO2005060935A1 (ja) 薬物を含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる非経口投与用製剤
JP7780442B2 (ja) メチル｛４，６－ジアミノ－２－［５－フルオロ－１－（２－フルオロベンジル）－１Ｈ－ピラゾロ［３，４－ｂ］ピリジン－３－イル］ピリミジン－５－イル｝カルバメートのナノ製剤
CN109803684B (zh) 用于治疗肝细胞癌的组合疗法
JP2015510935A (ja) 封入ジエチレントリアミンペンタアセテート粒子の経口送達のための組成物および方法
JP5300477B2 (ja) 薬理活性物質の吸収性が改善された医薬組成物
KR20120094178A (ko) 레바프라잔-함유 나노입자를 포함하는 경구투여용 약학 조성물 및 그의 제조방법
Zhang et al. A novel oil-based suspension of a micro-environmental, pH-modifying solid dispersion for parenteral delivery: Formulation and stability evaluation
JPWO2006073154A1 (ja) 医薬組成物及びその製造方法
JPWO2020045456A1 (ja) 薬物含有粒子
JPH0892088A (ja) 経口投与用油性組成物
CN1615899B (zh) 葛根素口服制剂
KR101476096B1 (ko) 용해도가 향상된 쎄레콕시브의 약제학적 조성물
TWI597063B (zh) 藥物組成物及其製備方法
JP5106119B2 (ja) シクロオキシゲナーゼ−２阻害剤を含む経口投与用の薬剤、およびその調製方法
JPS6136217A (ja) 経口投与用持効性製剤
BR112019016400A2 (pt) composições de complexos de gálio (iii) para administração oral
WO2007052738A1 (ja) 薬物の吸収性が改善された医薬組成物
JP2025502120A (ja) プロゲリニンを含む顆粒剤及びそれを用いたサシェ剤
JP2018044017A (ja) 粒子製剤
BR122024025108A2 (pt) Composição farmacêutica sólida, processos para preparação da mesma e usos de um composto pirazólico na fabricação da referida composição para tratar dermatite atópica

Legal Events

Date Code Title Description
A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100225

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100407

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100907

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100908

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4588791

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130917

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees